These two stocks are so similar - AFFY and ARQL Both have Japanese partnership - Both were at $8 and then lowered to $4 and then after the drug is approved, it rocketed to the moon! Be paatient folks ARQL cancer fighting drug, once approved, will take you to the moon. Within the next 6 - 12 months time frame, IMO
I would say, 6-12 months to approval is somewhat optimistics. But
- HCC 300-pts trial can be fully enrolled in ~ 6 months plus 7-8 months to go plus 2-3 month to review. So the results by 1H 2014
- MARQUEE results and the Tiva future utility in NSCLC is by March-Apr 2013
- The same March-Apr 2013 time frame for PhII results in mCRC and prostate
The bottom line: the next 6 months will be very very eventful for ARQL. Just let us hope the management will not screw up anything as they did with MARQUEE.
1H 2014 would be optimistic I think but maybe. I still think CRC results critical here. Seems like HCC Ph 1, best result was Stable Disease but they got very good PFS and OS result in Ph 2. With CRC, Ph1 results (admitedly very small pop), results included complete and partial responses so hopefully would translate into good PFS and OS...we'll see...opinion?